Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001930
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Treatment of Huntingtons Chorea With Amantadine
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
NMDA-Receptor Blockade in Huntingtons Chorea
Status:
COMPLETED
Status Verified Date:
2000-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Huntingtons disease is a chronic disorder passed on through genetic autosomal dominant inheritance The condition usually begins between the ages of 30 and 50 years and it is characterized by involuntary movements in the face and extremities chorea accompanied by changes in behavior and gradual loss of the mental function The disease typically ends in a state of disorientation impaired memory judgement and intellect dementia
The objective of this study is to test the effectiveness of the drug amantadine for the treatment of chorea associated with Huntingtons disease Amantadine is an antiviral drug that has been used to treat a variety of illnesses including Parkinsons disease Amantadine works by attaching to special sites called NMDA N-methyl-D-aspartate receptors and blocking the normal activity of glutamate there Glutamate is an amino acid released by brain cells and has been associated with the symptoms of Parkinsons disease
The objective of this study is to test the effectiveness of the drug amantadine for the treatment of chorea associated with Huntingtons disease Amantadine is an antiviral drug that has been used to treat a variety of illnesses including Parkinsons disease Amantadine works by attaching to special sites called NMDA N-methyl-D-aspartate receptors and blocking the normal activity of glutamate there Glutamate is an amino acid released by brain cells and has been associated with the symptoms of Parkinsons disease
Detailed Description:
The objective of this study is to evaluate the acute effects of the putative NMDA-receptor antagonist amantadine on chorea of patients with Huntingtons disease HD Participants in this study will have mild to moderate HD associated with chorea
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-N-0098 | None | None | None |